ArticleFrontiers in endocrinology2026
SGLT2 inhibition, uric acid and inflammation in glycemic burden-related progression of cardiac autonomic neuropathy in type 2 diabetes mellitus: insights from machine learning and mediation analysis.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify independent predictors of diabetic cardiac autonomic neuropathy (DCAN) deterioration in patients with type 2 diabetes mellitus (T2DM), develop machine learning (ML)-based risk prediction models, and explore the underlying mediation of glycemic burden. Methods: This prospective cohort study included 293 T2DM patients who underwent standardized Ewing testing at baseline and follow-up. Univariable and multivariable logistic regression were utilized to identify predictors. Restricted cubic splines (RCS) were applied to evaluate non-linear relationships. Nine ML algorithms were developed and evaluated using AUC and calibration metrics, with SHAP values illustrating feature importance. Mediation analysis was performed to investigate whether longitudinal biomarker changes accounted for the association between HbA1c and DCAN deterioration. Results: During follow-up, 80 patients (27.3%) experienced DCAN deterioration. Multivariable logistic regression identified elevated HbA1c at baseline as an independent risk factor, while SGLT2 inhibitor use was significantly associated with a lower risk of deterioration. RCS analysis revealed a continuous linear risk increase for HbA1c at baseline, whereas the platelet-to-lymphocyte ratio (PLR) at baseline exhibited an inverted U-shaped relationship. Among the ML algorithms, KNN achieved the highest AUC among models meeting the prespecified calibration criterion (AUC = 0.913; Brier score = 0.084; calibration slope = 0.701; calibration intercept = -0.053). SHAP analysis confirmed SGLT2 inhibitor use, HbA1c, and PLR as the top three predictors. Mediation analysis demonstrated that longitudinal increases in uric acid (ΔUA) and white blood cell count (ΔWBC) accounted for 20.6% and 12.9% of the association between HbA1c and DCAN progression, respectively. Conclusions: SGLT2 inhibitor use is significantly associated with a lower risk of DCAN deterioration in T2DM patients, whereas elevated HbA1c levels correlate with disease progression, potentially involving pathways of exacerbated uric acid metabolism and systemic inflammation. Furthermore, the KNN-based ML model serves as a promising proof-of-concept tool for clinical risk stratification that warrants future external validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.